UK’s NICE recommends QUVIVIQ to treat chronic insomnia in adults
The National Institute for Health and Care Excellence (NICE) has recommended Idorsia UK’s QUVIVIQ (daridorexant) to treat chronic insomnia in adults.
The National Institute for Health and Care Excellence (NICE) has recommended Idorsia UK’s QUVIVIQ (daridorexant) to treat chronic insomnia in adults.
Eli Lilly and Company (Lilly) has completed the acquisition of clinical-stage biopharmaceutical firm Versanis Bio.
BioCryst Pharmaceuticals has signed a collaboration agreement with Er-Kim Pharmaceuticals for commercialising ORLADEYO (berotralstat) in Turkey.
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.
Intercept Pharmaceuticals has received orphan drug designation from US Food and Drug Administration (FDA) for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate to treat individuals with primary biliary cholangitis (PBC).
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial disease.
California-based AcelRx Pharmaceuticals has completed the divestment of DSUVIA to Alora Pharmaceuticals.
The US Food and Drug Administration (FDA) has granted fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 that helps to lower triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
Biotechnology firm Mediar Therapeutics has announced a $105m financing, which includes a recent $85m Series A round.
US Food and Drug Administration (FDA) has given approval to Nexus Pharmaceuticals for its Emerphed (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes.